PTU - Polskie Towarzystwo Urologiczne
home page
current numbers
archival numbers
list of articles:
list przewodni/covering letter
editor
Scientific Committee
publisher
subscription
advertising
important links

PROGNOSTIC VALUE OF PSA AFTER RADICAL PROSTATECTOMY
Article published in Urologia Polska 1999/52/1.

authors

Henryk Zieliński, Andrzej Łęcki
Klinika Urologii Centralnego Szpitala Klinicznego WAM w Warszawie
Kierownik Kliniki: prof. dr hab. n. med. B. Stawarz

keywords

prostate prostate cancer radical prostatectomy prostate specific antigen

summary

Introduction. Radical prostatectomy (RP) includes resection of the prostate,
capsula and regional lymph-nodes and therefore, the serum level of specific
prostate antigen (PSA) should be undetectable or close to zero. The aim of this
study is the evaluation of PSA in prognosis and diagnosis of recurrence in
prostate cancer patients after RP.
Material and methods. During 1992-1997 39 suprapubical RP's were
performed. Age of patients ranged between 45-74 (mean 65 ? 13. 2). Staging:
pT1 - 10, pT2 - 17, pT3a - 8, pT3b - 3, pT3c - 1 patient, N+ - 6 patients,
grading G1 ? 12, G2 ? 21, G3 ? 6 patients. Period of observation ranged
between 4-60 months. PSA was determined before surgery, every 3 months
during the lst year, every 4 months during the 2nd year and every 6 months
thereafter.
Results. In the first 3 months following RP the levels of PSA were: group I
0.01-0.1 ng/ml) - 22 patients; group II (011-0.4 ng/ml
> 0.4 ng/ml
prostate cancer, while in groups II and III 3 patients had recurrences. In patients
with metastases to lymph-nodes PSA values were higher than 0.75 ng/ml.
Conclusions. 1. Determination of PSA level after RP allows to evaluate the
radicality of surgery, to monitor the patients and earlier diagnosis of
recurrence. 2. If the level of PSA is close to zero, the possibility of local
recurrency and/or of tumour spread is low.

references

  1. [1] Abi-Aad, A., Macfarlane, M., Stein, A., deKernion, }.: Detection of local
  2. recurrence after radical prostatectomy by prostate specific antigen and trans-
  3. rectal ultrasound. J. Urol. 1992, 147, 952-955.
  4. [2] Andriole, G.: Adjuimnt therapy for prostate cancer patients at high risk of
  5. recurrence following radical prostatectomy. Eur. Urol. 1997, 32, .65-69.
  6. [3] Borkowski, A., Borówka, A.: Choroby gruczołu krokowego. PZWL, War-
  7. szawa 1997, 5, 67-85.
  8. [4] Frazier, H., Robertson, J., Humphrey, P, Paulson, D.: Is prostate specific
  9. antigen of clinical importance in evaluating outcome after radical prostatecto-
  10. my? J. Urol. 1993,148, 516-518.
  11. [5] Goldrath, D., Messing, E.: Prostate specific antigen not detectable despite
  12. tumor progression after radical prostatectomy. J. Urol. 1989, 142, 1082-1084.
  13. [6] Hudson, M., Bahnson, R., Catalona, W.: Clinical use of prostate specific
  14. antigen in patients with prostate cancer. J. Urol. 1989, 142, 1011-1017.
  15. [7] Lange, P., Ercole, C, Lightner, D.: The value of serum prostate specific
  16. antigen determinations before and after radical prostatectomy. T. Urol. 1989,
  17. 141, 873-879.
  18. [8] Lange, P, Lightner, D., Medini, E., Reddy, P, Vessella, R.: The effect of
  19. radiation therapy after radical prostatectomy in patients with elevated prosta-
  20. te specific antigen levels. J. Urol. 1990, 144,' 927-933.
  21. [9] Link, P, -Freiha, F., Stamey, T.: Adjuyant radiation therapy in patients with
  22. detectable prostate specific antigen following radical prostatectomy. J. Urol.
  23. 1991, 145, 532-534.
  24. [10] Marczyńska, A., Kulpa, J.: Swoisty antygen sterczowy (PSA): ocena użyte-
  25. czności w klinice raka stercza. Urol. Pol. 1992, 45, 69-76.
  26. [11] Oesterling, J., Chan, D., Epstein, I., Kimball, A., Bruzek, D., Rock, R.,
  27. Brendler, C, Walsh, P: Prostate specific antigen in the preoperative and
  28. postoperative evaluation of localized prostatic cancer treated with radical
  29. prostatectomy. J. Urol. 1988, 139, 766-772.
  30. [12] Oesterling, J.: Prostate specific antigen: A critical assessment of the most useful
  31. tumor marker for adenocarcinoma of the prostate. J. Urol. 1991,145,907-923.
  32. [13] Partin, A., Pound, C, Clemens, J., Epstein, J., Walsh, P.: Serum PSAafter
  33. anatomic radical prostatectomy: The Urologic Clinics of North America Pro-
  34. static Tumor Markers. Red. J. E. Osterling, Philadelphia 1993, 20, 4, 713-725.
  35. [14] Paulson, D., Moul, J., Walther, P.: Radical prostatectomy for clinical stage
  36. T1- 2, No, Mo prostatic carcinoma, Long-term results. J. Urol. 1990, 144, 1180-
  37. -1184.
  38. [15] Schild, S., Wong, W., Nowicki, D., Ferrigni, R., Swanson, S.: Detection of
  39. residual prostate cancer after radical prostatectomy with the Abbott Imx PSA assay.
  40. Urology 1996, 47, 878-881.
  41. [16] Stamey, T., Ferrari, M., Schmid, H.: The value of serial prostate specific-
  42. antigen determinations 5 years after radiotherapy. Steeply increasing values charac-
  43. terize 80% of patients. J. Urol. 1993,150,1856-1859.
  44. [17] Stein, A., de Kernion, J., Dorey, F.: Prostatic specific antigen related to clinical
  45. status 1 to l4 years after radical retropubic prostatectomy. Br. J. Urol. 1991,67,626-
  46. 631.
  47. [18] Stokłosa, A.: Specyficzny antygen sterczowy (PSA) w patologii gruczołu kroko-
  48. wego. Medycyna 2000,1993, 41/42, 45-51.
  49. [19] Zincke, H., Bergstralh, E., Larson-Keller, ]., Farrow, G., Myers, R., Lie-
  50. ber, M., Barret, D., Rife, C, Gonchoroff, N.: Stage D-l prostate cancer
  51. treated by radical prostatectomy and adjuyant hormonal treatment. Evidence
  52. for favorable survival in patients with DNA diploid tumors. Cancer 1992, 70,
  53. 311-323.